HRP20240694T1 - Inhibitori arginaze i postupci njihove upotrebe - Google Patents

Inhibitori arginaze i postupci njihove upotrebe Download PDF

Info

Publication number
HRP20240694T1
HRP20240694T1 HRP20240694TT HRP20240694T HRP20240694T1 HR P20240694 T1 HRP20240694 T1 HR P20240694T1 HR P20240694T T HRP20240694T T HR P20240694TT HR P20240694 T HRP20240694 T HR P20240694T HR P20240694 T1 HRP20240694 T1 HR P20240694T1
Authority
HR
Croatia
Prior art keywords
boraspiro
aza
oxa
oxo
hydroxy
Prior art date
Application number
HRP20240694TT
Other languages
English (en)
Croatian (hr)
Inventor
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20240694T1 publication Critical patent/HRP20240694T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20240694TT 2018-08-22 2019-08-21 Inhibitori arginaze i postupci njihove upotrebe HRP20240694T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof
EP19758683.7A EP3840837B1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20240694T1 true HRP20240694T1 (hr) 2024-08-16

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240694TT HRP20240694T1 (hr) 2018-08-22 2019-08-21 Inhibitori arginaze i postupci njihove upotrebe

Country Status (25)

Country Link
US (1) US11952392B2 (enExample)
EP (2) EP4371614A3 (enExample)
JP (1) JP7441210B2 (enExample)
KR (1) KR102668252B1 (enExample)
CN (1) CN112584900B (enExample)
AU (1) AU2019323663B2 (enExample)
CA (1) CA3109100A1 (enExample)
CL (1) CL2021000430A1 (enExample)
DK (1) DK3840837T3 (enExample)
EA (1) EA202190532A1 (enExample)
ES (1) ES2980252T3 (enExample)
FI (1) FI3840837T3 (enExample)
HR (1) HRP20240694T1 (enExample)
HU (1) HUE066903T2 (enExample)
IL (1) IL280924B2 (enExample)
LT (1) LT3840837T (enExample)
MA (1) MA53427B1 (enExample)
MX (1) MX2021002042A (enExample)
PL (1) PL3840837T3 (enExample)
PT (1) PT3840837T (enExample)
RS (1) RS65608B1 (enExample)
SG (1) SG11202101618PA (enExample)
SI (1) SI3840837T1 (enExample)
SM (1) SMT202400221T1 (enExample)
WO (1) WO2020038983A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4239652A4 (en) 2020-12-25 2024-06-05 Sumitomo Riko Company Limited Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3840837B1 (en) 2024-03-20
SMT202400221T1 (it) 2024-07-09
JP7441210B2 (ja) 2024-02-29
CA3109100A1 (en) 2020-02-27
EP4371614A2 (en) 2024-05-22
KR102668252B1 (ko) 2024-05-21
US20210332068A1 (en) 2021-10-28
PL3840837T3 (pl) 2024-08-19
MA53427B1 (fr) 2024-06-28
MX2021002042A (es) 2021-04-28
WO2020038983A1 (en) 2020-02-27
KR20210049120A (ko) 2021-05-04
US11952392B2 (en) 2024-04-09
RS65608B1 (sr) 2024-07-31
CN112584900B (zh) 2025-07-15
IL280924B2 (en) 2024-10-01
HUE066903T2 (hu) 2024-09-28
IL280924B1 (en) 2024-06-01
SI3840837T1 (sl) 2024-07-31
EP3840837A1 (en) 2021-06-30
MA53427A (fr) 2021-12-01
DK3840837T3 (da) 2024-06-10
JP2021535111A (ja) 2021-12-16
EA202190532A1 (ru) 2021-07-08
AU2019323663B2 (en) 2022-07-14
IL280924A (en) 2021-04-29
SG11202101618PA (en) 2021-03-30
ES2980252T3 (es) 2024-09-30
LT3840837T (lt) 2024-06-10
AU2019323663A1 (en) 2021-04-08
FI3840837T3 (fi) 2024-06-03
EP4371614A3 (en) 2025-09-24
CL2021000430A1 (es) 2021-09-03
PT3840837T (pt) 2024-06-14
CN112584900A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
FI3840837T3 (fi) Arginaasin estäjät ja menetelmät niiden käyttämiseksi
HRP20211622T1 (hr) 4'-supstituirani nukleozidni-derivati kao inhibitori hiv reverzne transkriptaze
HRP20201681T1 (hr) Inhibitor aurora a kinaze
BR112021023347A2 (pt) Compostos de pirrolidina
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
HRP20120066T1 (hr) Kalijeva sol inhibitora hiv integraze
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HRP20202073T1 (hr) Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori
HRP20140666T1 (hr) Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
HRP20250459T1 (hr) Čvrsti oblici i kombinacijski pripravci koji sadrže inhibitor beta-laktamaze i njihove uporabe
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
HRP20171924T1 (hr) 6-o-supstituirani spojevi benzoksazola i benzotiazola te postupci inhibiranja signalizacije csf-1r
HRP20200408T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
MX2024014346A (es) Compuestos de indolinilo antivirales y usos de estos
HRP20220829T1 (hr) Kristalni spojevi
HRP20171041T1 (hr) Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže
PH12020550580A1 (en) Immunoproteasome inhibitors
HRP20231369T1 (hr) Inhibitori lsd1 i njihova medicinska upotreba
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
IL276194B2 (en) Pharmaceutical compounds or preparations containing them for use in the treatment of pain
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
EA201891413A1 (ru) Фармацевтическая композиция, содержащая безводный дазатиниб
HRP20240896T1 (hr) Derivati sulfoniluree i njihova upotreba